This recombinant monoclonal antibody is a research-grade biosimilar to Enoblituzumab, designed to specifically target CD276 (B7-H3), a member of the B7 family of immune checkpoint proteins. CD276 is a transmembrane glycoprotein that functions as an immune regulatory molecule, modulating T-cell activation and proliferation. Under normal physiological conditions, CD276 exhibits limited expression in healthy tissues, but becomes significantly overexpressed across numerous solid tumors, including bladder, prostate, lung, breast, and ovarian cancers. This aberrant expression correlates with tumor progression, metastasis, and poor clinical prognosis, making CD276 an attractive target for cancer immunotherapy research.
Enoblituzumab, the reference antibody, is a humanized IgG1 monoclonal antibody that has been investigated in clinical trials for various malignancies, particularly head and neck squamous cell carcinoma and bladder cancer. This biosimilar provides researchers with a valuable tool for investigating CD276-mediated immune evasion mechanisms, tumor microenvironment interactions, and potential therapeutic strategies targeting this checkpoint molecule. The antibody supports diverse oncology research applications exploring novel immunotherapeutic approaches.
Email: support@cusabio.com
Distributors Worldwide